Leading Korean pharmaceutical manufacturer transforms drug processing with Quantum 600 pump
- Quantum 600 reduces transfer time by providing high flow rates even at high pressures
- Low pulsation prevents flowmeter instability
Efficiency is essential at every stage in the production of medicines in order to minimise waste and bring medicines to patients more quickly. This results in more profitable organisations and greater means to invest in research and development. Minimising processing time is therefore an important consideration to optimise the design of a drug manufacturing process.
Daewoong Pharmaceutical is one of Korea’s leading healthcare organisations, with the largest prescription drug sales in Korea, including 15 blockbuster products. One of the Company’s key products is Botulinum toxin, a neurotoxic protein used to treat a range of medical conditions including muscle spasticity and migraine, as well as for cosmetic procedures (commonly known as Botox).
High flowrate at high pressure
During the filtration of Botulinium toxin, Daewoong encountered a problem of reducing flowrate at high pressure, leading to increased transfer time. The Company required a pump that could achieve high flowrates (10-15 l/min) even at high pressures (2.5-3.0 bar). Quantum 600 pump from Watson-Marlow Fluid Technology Group (WMFTG) was chosen to overcome this problem, significantly reducing transfer time.
Designed specifically for bioprocessing applications, the Quantum 600 offers the added benefit of ultra-low pulsation due to its peristaltic design which guarantees low sheer. Consistent pressure prevents flowmeter instability and improves the reliability of the filtration process.
Extensive industry expertise
Daewoong pharmaceutical not only required efficient flow in high flowrate, high pressure situations but also in high flowrate, low pressure situations. WMFTG used its extensive knowledge of biopharmaceutical processing to suggest a flexible combined system, satisfying both these requirements. A 730SN/R pump was provided alongside the Quantum 600, for application in high flowrate, low pressure situations.
In-depth industry knowledge enables WMFTG engineers to provide bespoke solutions to manufacturing challenges. The breadth of the WMFTG product portfolio allows for an optimal solution to be developed, be that from a single component or integrated system.
For further information, please contact:
Joanne Lucas, Group Marketing PR Coordinator
T: +44 (0) 1326 370 214
Juliette Craggs / Victoria Deaner / Deborah Cockerill
T: +44 (0)20 3405 7892
Notes to Editors
About Watson-Marlow Fluid Technology Group
Watson-Marlow Fluid Technology Group is part of Spirax-Sarco Engineering plc, a FTSE 100 company. The company is an award-winning, global leader in fluid management technology and for over 60 years has engineered components and systems for customers in a wide range of pharmaceutical and industrial markets. Learn more at www.wmftg.com or @WMFTG_news.BiotechnologyCase StudyPharmaceutical